You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameBendroflumethiazide
Accession NumberDB00436  (APRD00666)
TypeSmall Molecule
GroupsApproved
DescriptionA thiazide diuretic with actions and uses similar to those of hydrochlorothiazide. It has been used in the treatment of familial hyperkalemia, hypertension, edema, and urinary tract disorders. (From Martindale, The Extra Pharmacopoeia, 30th ed, p810)
Structure
Thumb
Synonyms
+--3-Benzyl-3,4-dihydro-6-(trifluoromethyl)-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide
6-Trifluoromethyl-3-benzyl-7-sulfamyl-3,4-dihydro-1,2,4-benzothiadiazine 1,1-dioxide
Bendrofluazide
Bendroflumethiazid
Bendrofluméthiazide
Bendroflumethiazidum
Bendroflumetiazida
Benzhydroflumethiazide
External Identifiers
  • BE 724-A
  • FT 81
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Naturetin 5mgtablet5 mgoralSquibb Canada Inc., Division Of Bristol Myers Squibb Canada Inc.1959-12-311999-01-07Canada
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
AprinoxSovereign Medical
CentylLEO Pharma
NaturetinNot Available
Neo-NaclexGlaxoSmithKline
SaluresPfizer
Brand mixtures
NameLabellerIngredients
CorzidePfizer Laboratories Div Pfizer Inc
Corzide Tab W Nadolol 40mgSquibb Canada Inc., Division Of Bristol Myers Squibb Canada Inc.
Corzide Tab W Nadolol 80mgSquibb Canada Inc., Division Of Bristol Myers Squibb Canada Inc.
Nadolol and BendroflumethiazideImpax Generics
SaltsNot Available
Categories
UNII5Q52X6ICJI
CAS number73-48-3
WeightAverage: 421.415
Monoisotopic: 421.037781946
Chemical FormulaC15H14F3N3O4S2
InChI KeyInChIKey=HDWIHXWEUNVBIY-UHFFFAOYSA-N
InChI
InChI=1S/C15H14F3N3O4S2/c16-15(17,18)10-7-11-13(8-12(10)26(19,22)23)27(24,25)21-14(20-11)6-9-4-2-1-3-5-9/h1-5,7-8,14,20-21H,6H2,(H2,19,22,23)
IUPAC Name
3-benzyl-1,1-dioxo-6-(trifluoromethyl)-3,4-dihydro-2H-1λ⁶,2,4-benzothiadiazine-7-sulfonamide
SMILES
NS(=O)(=O)C1=CC2=C(NC(CC3=CC=CC=C3)NS2(=O)=O)C=C1C(F)(F)F
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as benzothiadiazines. These are organic compounds containing a benzene fused to a thiadiazine ring (a six-member ring with two nitrogen atoms and a sulfur atom).
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassThiadiazines
Sub ClassBenzothiadiazines
Direct ParentBenzothiadiazines
Alternative Parents
Substituents
  • Benzothiadiazine
  • Secondary aliphatic/aromatic amine
  • Aminosulfonyl compound
  • Sulfonyl
  • Sulfonic acid derivative
  • Sulfonamide
  • Azacycle
  • Secondary amine
  • Hydrocarbon derivative
  • Organosulfur compound
  • Organonitrogen compound
  • Organofluoride
  • Organohalogen compound
  • Amine
  • Alkyl halide
  • Alkyl fluoride
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External DescriptorsNot Available
Pharmacology
IndicationFor the treatment of high blood pressure and management of edema related to heart failure.
PharmacodynamicsBendroflumethiazide, a thiazide diuretic, removes excess water from the body by increasing how often you urinate (pass water) and also widens the blood vessels which helps to reduce blood pressure. It inhibits Na+/Cl- reabsorption from the distal convoluted tubules in the kidneys. Thiazides also cause loss of potassium and an increase in serum uric acid. Thiazides are often used to treat hypertension, but their hypotensive effects are not necessarily due to their diuretic activity. Thiazides have been shown to prevent hypertension-related morbidity and mortality although the mechanism is not fully understood. Thiazides cause vasodilation by activating calcium-activated potassium channels (large conductance) in vascular smooth muscles and inhibiting various carbonic anhydrases in vascular tissue.
Mechanism of actionAs a diuretic, bendroflumethiazide inhibits active chloride reabsorption at the early distal tubule via the Na-Cl cotransporter, resulting in an increase in the excretion of sodium, chloride, and water. Thiazides like bendroflumethiazide also inhibit sodium ion transport across the renal tubular epithelium through binding to the thiazide sensitive sodium-chloride transporter. This results in an increase in potassium excretion via the sodium-potassium exchange mechanism. The antihypertensive mechanism of bendroflumethiazide is less well understood although it may be mediated through its action on carbonic anhydrases in the smooth muscle or through its action on the large-conductance calcium-activated potassium (KCa) channel, also found in the smooth muscle.
Related Articles
AbsorptionAbsorbed relatively rapidly after oral administration
Volume of distributionNot Available
Protein binding96%
MetabolismNot Available
Route of eliminationNot Available
Half life8.5 hours
ClearanceNot Available
ToxicityNot Available
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Bendroflumethiazide Action PathwayDrug actionSMP00090
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9643
Blood Brain Barrier-0.7807
Caco-2 permeable-0.7105
P-glycoprotein substrateNon-substrate0.6048
P-glycoprotein inhibitor INon-inhibitor0.7889
P-glycoprotein inhibitor IINon-inhibitor0.8383
Renal organic cation transporterNon-inhibitor0.8835
CYP450 2C9 substrateNon-substrate0.708
CYP450 2D6 substrateNon-substrate0.8398
CYP450 3A4 substrateNon-substrate0.6596
CYP450 1A2 substrateInhibitor0.8745
CYP450 2C9 inhibitorNon-inhibitor0.907
CYP450 2D6 inhibitorNon-inhibitor0.9351
CYP450 2C19 inhibitorNon-inhibitor0.9287
CYP450 3A4 inhibitorNon-inhibitor0.8607
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9081
Ames testNon AMES toxic0.8474
CarcinogenicityNon-carcinogens0.8156
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.0888 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9858
hERG inhibition (predictor II)Non-inhibitor0.8967
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Apothecon inc div bristol myers squibb
Packagers
Dosage forms
FormRouteStrength
Tabletoral
Tabletoral5 mg
Prices
Unit descriptionCostUnit
Bendroflumethiazide powder45.0USD g
Corzide 80-5 tablet4.29USD tablet
Corzide 40-5 mg tablet3.46USD tablet
Corzide 40-5 tablet3.35USD tablet
Corzide 80-5 mg tablet3.23USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point222-223 °CGoldberg, M.; U.S. Patent 3,265,573; August 9, 1966; assigned to E.R. Squibb & Sons, Inc. Lund, F., Lyngby, K. and Godtfredsen, W.O.; U.S. Patent 3,392,168; July 9, 1968; assigned to Lovens Kemiske Fabrik ved A. Kongsted, Denmark.
water solubility108 mg/L (at 25 °C)YALKOWSKY,SH & DANNENFELSER,RM (1992)
logP1.89BERTHOD,A ET AL. (1999)
logS-3.59ADME Research, USCD
pKa8.5SANGSTER (1994)
Predicted Properties
PropertyValueSource
Water Solubility0.214 mg/mLALOGPS
logP1.83ALOGPS
logP1.7ChemAxon
logS-3.3ALOGPS
pKa (Strongest Acidic)9.04ChemAxon
pKa (Strongest Basic)-3.1ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area118.36 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity93.68 m3·mol-1ChemAxon
Polarizability36.92 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis Reference

Goldberg, M.; U.S. Patent 3,265,573; August 9, 1966; assigned to E.R. Squibb & Sons, Inc. Lund, F., Lyngby, K. and Godtfredsen, W.O.; U.S. Patent 3,392,168; July 9, 1968; assigned
to Lovens Kemiske Fabrik ved A. Kongsted, Denmark.

General ReferencesNot Available
External Links
ATC CodesC03AA01C03EA13C03AB01
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSDownload (72.8 KB)
Interactions
Drug Interactions
Drug
4-Androstenedione4-Androstenedione may increase the hypokalemic activities of Bendroflumethiazide.
7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE may increase the hypotensive activities of Bendroflumethiazide.
AcarboseThe therapeutic efficacy of Acarbose can be decreased when used in combination with Bendroflumethiazide.
AcebutololBendroflumethiazide may increase the hypotensive activities of Acebutolol.
AceclofenacThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Aceclofenac.
AcetazolamideThe risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Acetazolamide.
AcetohexamideThe therapeutic efficacy of Acetohexamide can be decreased when used in combination with Bendroflumethiazide.
AcetyldigitoxinThe risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Acetyldigitoxin.
Acetylsalicylic acidThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Acetylsalicylic acid.
AclidiniumThe serum concentration of Bendroflumethiazide can be increased when it is combined with Aclidinium.
AdapaleneThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Adapalene.
AicarThe therapeutic efficacy of Aicar can be decreased when used in combination with Bendroflumethiazide.
AlclometasoneAlclometasone may increase the hypokalemic activities of Bendroflumethiazide.
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Bendroflumethiazide.
AldosteroneAldosterone may increase the hypokalemic activities of Bendroflumethiazide.
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Bendroflumethiazide.
AlfuzosinAlfuzosin may increase the hypotensive activities of Bendroflumethiazide.
AliskirenBendroflumethiazide may increase the hypotensive activities of Aliskiren.
AllopurinolThe risk of a hypersensitivity reaction to Allopurinol is increased when it is combined with Bendroflumethiazide.
AlogliptinThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Bendroflumethiazide.
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Bendroflumethiazide.
AlprenololBendroflumethiazide may increase the hypotensive activities of Alprenolol.
AmbrisentanBendroflumethiazide may increase the hypotensive activities of Ambrisentan.
AmcinonideAmcinonide may increase the hypokalemic activities of Bendroflumethiazide.
AmifostineBendroflumethiazide may increase the hypotensive activities of Amifostine.
AmilorideThe risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Amiloride.
AmiodaroneBendroflumethiazide may increase the bradycardic activities of Amiodarone.
AmlodipineAmlodipine may increase the hypotensive activities of Bendroflumethiazide.
AmobarbitalAmobarbital may increase the orthostatic hypotensive activities of Bendroflumethiazide.
AmoxapineAmoxapine may increase the hyponatremic activities of Bendroflumethiazide.
Amyl NitriteThe risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Amyl Nitrite.
Anisotropine MethylbromideThe serum concentration of Bendroflumethiazide can be increased when it is combined with Anisotropine Methylbromide.
AntipyrineThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Antipyrine.
ApraclonidineThe risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Apraclonidine.
ApremilastThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Apremilast.
ArbutamineArbutamine may increase the hypokalemic activities of Bendroflumethiazide.
ArformoterolArformoterol may increase the hypokalemic activities of Bendroflumethiazide.
AripiprazoleAripiprazole may increase the hypotensive activities of Bendroflumethiazide.
AtenololAtenolol may increase the hypotensive activities of Bendroflumethiazide.
Atracurium besylateThe serum concentration of Bendroflumethiazide can be increased when it is combined with Atracurium besylate.
AtropineThe serum concentration of Bendroflumethiazide can be increased when it is combined with Atropine.
AzapropazoneThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Azapropazone.
AzelastineThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Azelastine.
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Azilsartan medoxomil.
BalsalazideThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Balsalazide.
BambuterolBambuterol may increase the hypokalemic activities of Bendroflumethiazide.
BarbitalBarbital may increase the orthostatic hypotensive activities of Bendroflumethiazide.
Beclomethasone dipropionateBeclomethasone dipropionate may increase the hypokalemic activities of Bendroflumethiazide.
BenactyzineThe serum concentration of Bendroflumethiazide can be increased when it is combined with Benactyzine.
BenazeprilBendroflumethiazide may increase the hypotensive activities of Benazepril.
BenmoxinBenmoxin may increase the hypotensive activities of Bendroflumethiazide.
BenoxaprofenThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Benoxaprofen.
BenzatropineThe serum concentration of Bendroflumethiazide can be increased when it is combined with Benzatropine.
BepridilBendroflumethiazide may increase the hypotensive activities of Bepridil.
BeractantBendroflumethiazide may increase the bradycardic activities of Beractant.
BetamethasoneBetamethasone may increase the hypokalemic activities of Bendroflumethiazide.
BetaxololBetaxolol may increase the hypotensive activities of Bendroflumethiazide.
BethanidineBethanidine may increase the hypotensive activities of Bendroflumethiazide.
BezitramideThe risk or severity of adverse effects can be increased when Bezitramide is combined with Bendroflumethiazide.
BimatoprostBendroflumethiazide may increase the hypotensive activities of Bimatoprost.
BiperidenThe serum concentration of Bendroflumethiazide can be increased when it is combined with Biperiden.
BisoprololBendroflumethiazide may increase the hypotensive activities of Bisoprolol.
BosentanBendroflumethiazide may increase the hypotensive activities of Bosentan.
BretyliumBretylium may increase the bradycardic activities of Bendroflumethiazide.
BretyliumBendroflumethiazide may increase the hypotensive activities of Bretylium.
BrimonidineBendroflumethiazide may increase the hypotensive activities of Brimonidine.
BrimonidineBrimonidine may increase the antihypertensive activities of Bendroflumethiazide.
BromfenacThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Bromfenac.
BudesonideBudesonide may increase the hypokalemic activities of Bendroflumethiazide.
BuforminThe therapeutic efficacy of Buformin can be decreased when used in combination with Bendroflumethiazide.
BumetanideThe risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Bumetanide.
BupranololBendroflumethiazide may increase the hypotensive activities of Bupranolol.
BuprenorphineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Bendroflumethiazide.
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Bendroflumethiazide.
CalfactantBendroflumethiazide may increase the bradycardic activities of Calfactant.
CanagliflozinThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Bendroflumethiazide.
CanagliflozinThe risk or severity of adverse effects can be increased when Canagliflozin is combined with Bendroflumethiazide.
CandesartanBendroflumethiazide may increase the hypotensive activities of Candesartan.
CandoxatrilBendroflumethiazide may increase the hypotensive activities of Candoxatril.
CaptoprilBendroflumethiazide may increase the hypotensive activities of Captopril.
CarbamazepineThe risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Carbamazepine.
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with Bendroflumethiazide.
CaroxazoneCaroxazone may increase the hypotensive activities of Bendroflumethiazide.
CarprofenThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Carprofen.
CarteololBendroflumethiazide may increase the hypotensive activities of Carteolol.
CarvedilolBendroflumethiazide may increase the hypotensive activities of Carvedilol.
CastanospermineThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Castanospermine.
CelecoxibThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Celecoxib.
CeliprololBendroflumethiazide may increase the hypotensive activities of Celiprolol.
CeritinibBendroflumethiazide may increase the bradycardic activities of Ceritinib.
ChloroquineThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Chloroquine.
ChlorothiazideBendroflumethiazide may increase the hypotensive activities of Chlorothiazide.
ChlorphenoxamineThe serum concentration of Bendroflumethiazide can be increased when it is combined with Chlorphenoxamine.
ChlorpropamideThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Bendroflumethiazide.
ChlorthalidoneChlorthalidone may increase the hypotensive activities of Bendroflumethiazide.
CholestyramineCholestyramine can cause a decrease in the absorption of Bendroflumethiazide resulting in a reduced serum concentration and potentially a decrease in efficacy.
CiclesonideCiclesonide may increase the hypokalemic activities of Bendroflumethiazide.
CiglitazoneThe therapeutic efficacy of Ciglitazone can be decreased when used in combination with Bendroflumethiazide.
CilazaprilBendroflumethiazide may increase the hypotensive activities of Cilazapril.
CitalopramCitalopram may increase the hyponatremic activities of Bendroflumethiazide.
ClenbuterolClenbuterol may increase the hypokalemic activities of Bendroflumethiazide.
ClevidipineThe risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Clevidipine.
Clobetasol propionateClobetasol propionate may increase the hypokalemic activities of Bendroflumethiazide.
ClocortoloneClocortolone may increase the hypokalemic activities of Bendroflumethiazide.
ClomipramineClomipramine may increase the hyponatremic activities of Bendroflumethiazide.
ClonidineBendroflumethiazide may increase the hypotensive activities of Clonidine.
ClonixinThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Clonixin.
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Bendroflumethiazide.
ColesevelamColesevelam can cause a decrease in the absorption of Bendroflumethiazide resulting in a reduced serum concentration and potentially a decrease in efficacy.
ColestipolColestipol can cause a decrease in the absorption of Bendroflumethiazide resulting in a reduced serum concentration and potentially a decrease in efficacy.
Cortisone acetateCortisone acetate may increase the hypokalemic activities of Bendroflumethiazide.
CrizotinibBendroflumethiazide may increase the bradycardic activities of Crizotinib.
CryptenamineBendroflumethiazide may increase the hypotensive activities of Cryptenamine.
CyclopentolateThe serum concentration of Bendroflumethiazide can be increased when it is combined with Cyclopentolate.
CyclophosphamideThe risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Cyclophosphamide.
CyclothiazideBendroflumethiazide may increase the hypotensive activities of Cyclothiazide.
D-LimoneneThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with D-Limonene.
DapagliflozinThe risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Dapagliflozin.
DapoxetineDapoxetine may increase the hyponatremic activities of Bendroflumethiazide.
DarifenacinThe serum concentration of Bendroflumethiazide can be increased when it is combined with Darifenacin.
DebrisoquinBendroflumethiazide may increase the hypotensive activities of Debrisoquin.
DehydroepiandrosteroneDehydroepiandrosterone may increase the hypokalemic activities of Bendroflumethiazide.
dehydroepiandrosterone sulfatedehydroepiandrosterone sulfate may increase the hypokalemic activities of Bendroflumethiazide.
DeserpidineBendroflumethiazide may increase the hypotensive activities of Deserpidine.
DeslanosideThe risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Deslanoside.
DesloratadineThe serum concentration of Bendroflumethiazide can be increased when it is combined with Desloratadine.
DesoximetasoneDesoximetasone may increase the hypokalemic activities of Bendroflumethiazide.
Desoxycorticosterone acetateDesoxycorticosterone acetate may increase the hypokalemic activities of Bendroflumethiazide.
DexamethasoneDexamethasone may increase the hypokalemic activities of Bendroflumethiazide.
Dexamethasone isonicotinateDexamethasone isonicotinate may increase the hypokalemic activities of Bendroflumethiazide.
DexetimideThe serum concentration of Bendroflumethiazide can be increased when it is combined with Dexetimide.
DexketoprofenThe risk or severity of adverse effects can be increased when Dexketoprofen is combined with Bendroflumethiazide.
DexmedetomidineThe risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Dexmedetomidine.
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Bendroflumethiazide.
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Bendroflumethiazide.
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Bendroflumethiazide.
DiazoxideThe risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Diazoxide.
DiazoxideDiazoxide may increase the hypotensive activities of Bendroflumethiazide.
DiclofenacThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Diclofenac.
DiclofenamideThe risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Diclofenamide.
DicyclomineThe serum concentration of Bendroflumethiazide can be increased when it is combined with Dicyclomine.
DiflorasoneDiflorasone may increase the hypokalemic activities of Bendroflumethiazide.
DiflunisalThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Diflunisal.
DifluocortoloneDifluocortolone may increase the hypokalemic activities of Bendroflumethiazide.
DifluprednateDifluprednate may increase the hypokalemic activities of Bendroflumethiazide.
DigitoxinThe risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Digitoxin.
DigoxinThe risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Digoxin.
DigoxinDigoxin may increase the bradycardic activities of Bendroflumethiazide.
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Bendroflumethiazide.
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Bendroflumethiazide.
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Bendroflumethiazide.
DiltiazemDiltiazem may increase the hypotensive activities of Bendroflumethiazide.
DinutuximabThe risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Dinutuximab.
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Bendroflumethiazide.
DipivefrinDipivefrin may increase the hypokalemic activities of Bendroflumethiazide.
DipyridamoleThe risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Dipyridamole.
DobutamineDobutamine may increase the hypokalemic activities of Bendroflumethiazide.
DofetilideBendroflumethiazide may increase the QTc-prolonging activities of Dofetilide.
DonepezilBendroflumethiazide may increase the bradycardic activities of Donepezil.
DorzolamideBendroflumethiazide may increase the hypotensive activities of Dorzolamide.
DoxazosinBendroflumethiazide may increase the hypotensive activities of Doxazosin.
DPDPEThe risk or severity of adverse effects can be increased when DPDPE is combined with Bendroflumethiazide.
DronedaroneBendroflumethiazide may increase the bradycardic activities of Dronedarone.
DroxicamThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Droxicam.
DroxidopaDroxidopa may increase the hypokalemic activities of Bendroflumethiazide.
DulaglutideThe therapeutic efficacy of Dulaglutide can be decreased when used in combination with Bendroflumethiazide.
DuloxetineBendroflumethiazide may increase the orthostatic hypotensive activities of Duloxetine.
EfonidipineBendroflumethiazide may increase the hypotensive activities of Efonidipine.
EmpagliflozinThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Bendroflumethiazide.
EmpagliflozinThe risk or severity of adverse effects can be increased when Empagliflozin is combined with Bendroflumethiazide.
EnalaprilBendroflumethiazide may increase the hypotensive activities of Enalapril.
EnalaprilatBendroflumethiazide may increase the hypotensive activities of Enalaprilat.
EphedraEphedra may increase the hypokalemic activities of Bendroflumethiazide.
EpinephrineEpinephrine may increase the hypokalemic activities of Bendroflumethiazide.
EpirizoleThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Epirizole.
EplerenoneThe risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Eplerenone.
EpoprostenolBendroflumethiazide may increase the hypotensive activities of Epoprostenol.
EprosartanBendroflumethiazide may increase the hypotensive activities of Eprosartan.
EquileninEquilenin may increase the hypokalemic activities of Bendroflumethiazide.
EquilinEquilin may increase the hypokalemic activities of Bendroflumethiazide.
EscitalopramEscitalopram may increase the hyponatremic activities of Bendroflumethiazide.
EsmololThe risk or severity of adverse effects can be increased when Esmolol is combined with Bendroflumethiazide.
EstroneEstrone may increase the hypokalemic activities of Bendroflumethiazide.
Etacrynic acidThe risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Etacrynic acid.
EtanerceptThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Etanercept.
EthanolEthanol may increase the orthostatic hypotensive activities of Bendroflumethiazide.
EthopropazineThe serum concentration of Bendroflumethiazide can be increased when it is combined with Ethopropazine.
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Bendroflumethiazide.
EtodolacThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Etodolac.
EtofenamateThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Etofenamate.
EtoperidoneEtoperidone may increase the hyponatremic activities of Bendroflumethiazide.
EtoricoxibThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Etoricoxib.
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Bendroflumethiazide.
Evening primrose oilThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Evening primrose oil.
ExenatideThe therapeutic efficacy of Exenatide can be decreased when used in combination with Bendroflumethiazide.
exisulindThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with exisulind.
FelodipineBendroflumethiazide may increase the hypotensive activities of Felodipine.
FenbufenThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Fenbufen.
FenfluramineFenfluramine may increase the hyponatremic activities of Bendroflumethiazide.
FenoldopamBendroflumethiazide may increase the hypotensive activities of Fenoldopam.
FenoprofenThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Fenoprofen.
FenoterolFenoterol may increase the hypokalemic activities of Bendroflumethiazide.
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Bendroflumethiazide.
FesoterodineThe serum concentration of Bendroflumethiazide can be increased when it is combined with Fesoterodine.
FingolimodBendroflumethiazide may increase the bradycardic activities of Fingolimod.
FloctafenineThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Floctafenine.
FludrocortisoneFludrocortisone may increase the hypokalemic activities of Bendroflumethiazide.
FlumethasoneFlumethasone may increase the hypokalemic activities of Bendroflumethiazide.
FlunisolideFlunisolide may increase the hypokalemic activities of Bendroflumethiazide.
FlunixinThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Flunixin.
Fluocinolone AcetonideFluocinolone Acetonide may increase the hypokalemic activities of Bendroflumethiazide.
FluocinonideFluocinonide may increase the hypokalemic activities of Bendroflumethiazide.
FluocortoloneFluocortolone may increase the hypokalemic activities of Bendroflumethiazide.
FluorometholoneFluorometholone may increase the hypokalemic activities of Bendroflumethiazide.
FluoxetineFluoxetine may increase the hyponatremic activities of Bendroflumethiazide.
FluprednideneFluprednidene may increase the hypokalemic activities of Bendroflumethiazide.
FluprednisoloneFluprednisolone may increase the hypokalemic activities of Bendroflumethiazide.
FlurandrenolideFlurandrenolide may increase the hypokalemic activities of Bendroflumethiazide.
FlurbiprofenThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Flurbiprofen.
Fluticasone furoateFluticasone furoate may increase the hypokalemic activities of Bendroflumethiazide.
Fluticasone PropionateFluticasone Propionate may increase the hypokalemic activities of Bendroflumethiazide.
FluvoxamineFluvoxamine may increase the hyponatremic activities of Bendroflumethiazide.
FormoterolFormoterol may increase the hypokalemic activities of Bendroflumethiazide.
FosinoprilBendroflumethiazide may increase the hypotensive activities of Fosinopril.
FurazolidoneFurazolidone may increase the hypotensive activities of Bendroflumethiazide.
FurosemideThe risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Furosemide.
GalantamineBendroflumethiazide may increase the bradycardic activities of Galantamine.
Gallamine TriethiodideThe serum concentration of Bendroflumethiazide can be increased when it is combined with Gallamine Triethiodide.
GlibornurideThe therapeutic efficacy of Glibornuride can be decreased when used in combination with Bendroflumethiazide.
GliclazideThe therapeutic efficacy of Gliclazide can be decreased when used in combination with Bendroflumethiazide.
GlimepirideThe therapeutic efficacy of Glimepiride can be decreased when used in combination with Bendroflumethiazide.
GlipizideThe therapeutic efficacy of Glipizide can be decreased when used in combination with Bendroflumethiazide.
GliquidoneThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Bendroflumethiazide.
GlyburideThe therapeutic efficacy of Glyburide can be decreased when used in combination with Bendroflumethiazide.
GlycopyrroniumThe serum concentration of Bendroflumethiazide can be increased when it is combined with Glycopyrronium.
GuanabenzBendroflumethiazide may increase the hypotensive activities of Guanabenz.
GuanadrelGuanadrel may increase the hypotensive activities of Bendroflumethiazide.
GuanethidineBendroflumethiazide may increase the hypotensive activities of Guanethidine.
GuanfacineBendroflumethiazide may increase the hypotensive activities of Guanfacine.
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Bendroflumethiazide.
HexamethoniumBendroflumethiazide may increase the hypotensive activities of Hexamethonium.
HexobarbitalHexobarbital may increase the orthostatic hypotensive activities of Bendroflumethiazide.
HMPL-004The therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with HMPL-004.
HomatropineThe serum concentration of Bendroflumethiazide can be increased when it is combined with Homatropine.
HydracarbazineHydracarbazine may increase the hypotensive activities of Bendroflumethiazide.
HydralazineBendroflumethiazide may increase the hypotensive activities of Hydralazine.
HydrochlorothiazideBendroflumethiazide may increase the hypotensive activities of Hydrochlorothiazide.
HydrocodoneThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Bendroflumethiazide.
HydrocortisoneHydrocortisone may increase the hypokalemic activities of Bendroflumethiazide.
HydroflumethiazideBendroflumethiazide may increase the hypotensive activities of Hydroflumethiazide.
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Bendroflumethiazide.
HyoscyamineThe serum concentration of Bendroflumethiazide can be increased when it is combined with Hyoscyamine.
IbuprofenThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Ibuprofen.
IbuproxamThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Ibuproxam.
IcatibantThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Icatibant.
IloprostIloprost may increase the hypotensive activities of Bendroflumethiazide.
IndacaterolIndacaterol may increase the hypokalemic activities of Bendroflumethiazide.
IndalpineIndalpine may increase the hyponatremic activities of Bendroflumethiazide.
IndapamideBendroflumethiazide may increase the hypotensive activities of Indapamide.
IndenololBendroflumethiazide may increase the hypotensive activities of Indenolol.
IndomethacinThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Indomethacin.
IndoprofenThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Indoprofen.
IndoraminBendroflumethiazide may increase the hypotensive activities of Indoramin.
Insulin AspartThe therapeutic efficacy of Insulin Aspart can be decreased when used in combination with Bendroflumethiazide.
Insulin DetemirThe therapeutic efficacy of Insulin Detemir can be decreased when used in combination with Bendroflumethiazide.
Insulin GlargineThe therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Bendroflumethiazide.
Insulin GlulisineThe therapeutic efficacy of Insulin Glulisine can be decreased when used in combination with Bendroflumethiazide.
Insulin LisproThe therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Bendroflumethiazide.
Insulin PorkThe therapeutic efficacy of Insulin Pork can be decreased when used in combination with Bendroflumethiazide.
Ipratropium bromideThe serum concentration of Bendroflumethiazide can be increased when it is combined with Ipratropium bromide.
IproclozideIproclozide may increase the hypotensive activities of Bendroflumethiazide.
IproniazidIproniazid may increase the hypotensive activities of Bendroflumethiazide.
IrbesartanBendroflumethiazide may increase the hypotensive activities of Irbesartan.
IsocarboxazidIsocarboxazid may increase the hypotensive activities of Bendroflumethiazide.
IsoetarineIsoetarine may increase the hypokalemic activities of Bendroflumethiazide.
IsoprenalineIsoprenaline may increase the hypokalemic activities of Bendroflumethiazide.
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Isosorbide Dinitrate.
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Isosorbide Mononitrate.
IsoxicamThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Isoxicam.
IsoxsuprineThe risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Isoxsuprine.
IsradipineIsradipine may increase the hypotensive activities of Bendroflumethiazide.
IvabradineBendroflumethiazide may increase the arrhythmogenic activities of Ivabradine.
IvabradineIvabradine may increase the bradycardic activities of Bendroflumethiazide.
KebuzoneThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Kebuzone.
KetobemidoneThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Bendroflumethiazide.
KetoprofenThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Ketoprofen.
KetorolacThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Ketorolac.
LabetalolBendroflumethiazide may increase the hypotensive activities of Labetalol.
LacidipineBendroflumethiazide may increase the hypotensive activities of Lacidipine.
LacosamideBendroflumethiazide may increase the atrioventricular blocking (AV block) activities of Lacosamide.
LanreotideBendroflumethiazide may increase the bradycardic activities of Lanreotide.
LatanoprostBendroflumethiazide may increase the hypotensive activities of Latanoprost.
LeflunomideThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Leflunomide.
LercanidipineBendroflumethiazide may increase the hypotensive activities of Lercanidipine.
LevobunololThe risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Levobunolol.
LevodopaBendroflumethiazide may increase the orthostatic hypotensive activities of Levodopa.
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Bendroflumethiazide.
LevomilnacipranLevomilnacipran may increase the hyponatremic activities of Bendroflumethiazide.
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Bendroflumethiazide.
LicoriceLicorice may increase the hypokalemic activities of Bendroflumethiazide.
LinagliptinThe therapeutic efficacy of Linagliptin can be decreased when used in combination with Bendroflumethiazide.
LiraglutideThe therapeutic efficacy of Liraglutide can be decreased when used in combination with Bendroflumethiazide.
LisinoprilBendroflumethiazide may increase the hypotensive activities of Lisinopril.
LithiumBendroflumethiazide may decrease the excretion rate of Lithium which could result in a lower serum level and potentially a reduction in efficacy.
LofentanilThe risk or severity of adverse effects can be increased when Lofentanil is combined with Bendroflumethiazide.
LofexidineBendroflumethiazide may increase the hypotensive activities of Lofexidine.
LornoxicamThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Lornoxicam.
LosartanBendroflumethiazide may increase the hypotensive activities of Losartan.
LoxoprofenThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Loxoprofen.
Lu AA21004Lu AA21004 may increase the hyponatremic activities of Bendroflumethiazide.
LucinactantBendroflumethiazide may increase the bradycardic activities of Lucinactant.
LumiracoxibThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Lumiracoxib.
MacitentanBendroflumethiazide may increase the hypotensive activities of Macitentan.
Magnesium salicylateThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Magnesium salicylate.
ManidipineBendroflumethiazide may increase the hypotensive activities of Manidipine.
MannitolThe risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Mannitol.
MasoprocolThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Masoprocol.
MebanazineMebanazine may increase the hypotensive activities of Bendroflumethiazide.
MecamylamineThe risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Mecamylamine.
MecamylamineMecamylamine may increase the hypotensive activities of Bendroflumethiazide.
Meclofenamic acidThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Meclofenamic acid.
MedrysoneMedrysone may increase the hypokalemic activities of Bendroflumethiazide.
Mefenamic acidThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Mefenamic acid.
MelengestrolMelengestrol may increase the hypokalemic activities of Bendroflumethiazide.
MeloxicamThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Meloxicam.
MesalazineThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Mesalazine.
MetamizoleThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Metamizole.
MetforminThe therapeutic efficacy of Metformin can be decreased when used in combination with Bendroflumethiazide.
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Bendroflumethiazide.
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Bendroflumethiazide.
MethanthelineThe serum concentration of Bendroflumethiazide can be increased when it is combined with Methantheline.
MethazolamideThe risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Methazolamide.
MethohexitalMethohexital may increase the orthostatic hypotensive activities of Bendroflumethiazide.
MethyclothiazideThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Bendroflumethiazide.
MethyldopaBendroflumethiazide may increase the hypotensive activities of Methyldopa.
Methylene blueMethylene blue may increase the hypotensive activities of Bendroflumethiazide.
MethylphenidateMethylphenidate may decrease the antihypertensive activities of Bendroflumethiazide.
MethylphenobarbitalMethylphenobarbital may increase the orthostatic hypotensive activities of Bendroflumethiazide.
MethylprednisoloneMethylprednisolone may increase the hypokalemic activities of Bendroflumethiazide.
MetipranololBendroflumethiazide may increase the hypotensive activities of Metipranolol.
MetixeneThe serum concentration of Bendroflumethiazide can be increased when it is combined with Metixene.
MetolazoneBendroflumethiazide may increase the hypotensive activities of Metolazone.
MetoprololMetoprolol may increase the hypotensive activities of Bendroflumethiazide.
MibefradilBendroflumethiazide may increase the hypotensive activities of Mibefradil.
MiglitolThe therapeutic efficacy of Miglitol can be decreased when used in combination with Bendroflumethiazide.
MiglustatThe therapeutic efficacy of Miglustat can be decreased when used in combination with Bendroflumethiazide.
MilnacipranMilnacipran may increase the hyponatremic activities of Bendroflumethiazide.
MinaprineMinaprine may increase the hypotensive activities of Bendroflumethiazide.
MinoxidilMinoxidil may increase the hypotensive activities of Bendroflumethiazide.
MitiglinideThe therapeutic efficacy of Mitiglinide can be decreased when used in combination with Bendroflumethiazide.
MoclobemideMoclobemide may increase the hypotensive activities of Bendroflumethiazide.
MoexiprilBendroflumethiazide may increase the hypotensive activities of Moexipril.
MolsidomineMolsidomine may increase the hypotensive activities of Bendroflumethiazide.
MometasoneMometasone may increase the hypokalemic activities of Bendroflumethiazide.
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Bendroflumethiazide.
MoxonidineBendroflumethiazide may increase the hypotensive activities of Moxonidine.
Mycophenolate mofetilThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Mycophenolate mofetil.
Mycophenolic acidThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Mycophenolic acid.
N-butylscopolammonium bromideThe serum concentration of Bendroflumethiazide can be increased when it is combined with N-butylscopolammonium bromide.
NabumetoneThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Nabumetone.
NadololBendroflumethiazide may increase the hypotensive activities of Nadolol.
NaftifineThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Naftifine.
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Bendroflumethiazide.
NaproxenThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Naproxen.
NateglinideThe therapeutic efficacy of Nateglinide can be decreased when used in combination with Bendroflumethiazide.
NCX 4016The therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with NCX 4016.
NebivololBendroflumethiazide may increase the hypotensive activities of Nebivolol.
NepafenacThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Nepafenac.
NesiritideThe risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Nesiritide.
NialamideNialamide may increase the hypotensive activities of Bendroflumethiazide.
NicardipineBendroflumethiazide may increase the hypotensive activities of Nicardipine.
NicorandilNicorandil may increase the hypotensive activities of Bendroflumethiazide.
NifedipineThe risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Nifedipine.
Niflumic AcidThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Niflumic Acid.
NiguldipineBendroflumethiazide may increase the hypotensive activities of Niguldipine.
NilvadipineBendroflumethiazide may increase the hypotensive activities of Nilvadipine.
NimesulideThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Nimesulide.
NimodipineNimodipine may increase the hypotensive activities of Bendroflumethiazide.
NisoldipineNisoldipine may increase the hypotensive activities of Bendroflumethiazide.
NitrendipineBendroflumethiazide may increase the hypotensive activities of Nitrendipine.
NitroglycerinThe risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Nitroglycerin.
NitroprussideNitroprusside may increase the hypotensive activities of Bendroflumethiazide.
NorepinephrineNorepinephrine may increase the hypokalemic activities of Bendroflumethiazide.
NormethadoneThe risk or severity of adverse effects can be increased when Normethadone is combined with Bendroflumethiazide.
NVA237The serum concentration of Bendroflumethiazide can be increased when it is combined with NVA237.
ObinutuzumabBendroflumethiazide may increase the hypotensive activities of Obinutuzumab.
OctamoxinOctamoxin may increase the hypotensive activities of Bendroflumethiazide.
OctreotideOctreotide may increase the bradycardic activities of Bendroflumethiazide.
OlanzapineOlanzapine may increase the hyponatremic activities of Bendroflumethiazide.
OlmesartanOlmesartan may increase the hypotensive activities of Bendroflumethiazide.
OlodaterolOlodaterol may increase the hypokalemic activities of Bendroflumethiazide.
OlopatadineThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Olopatadine.
OlsalazineThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Olsalazine.
OmapatrilatBendroflumethiazide may increase the hypotensive activities of Omapatrilat.
OpiumThe risk or severity of adverse effects can be increased when Opium is combined with Bendroflumethiazide.
OrciprenalineOrciprenaline may increase the hypokalemic activities of Bendroflumethiazide.
OrgoteinThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Orgotein.
OrphenadrineThe serum concentration of Bendroflumethiazide can be increased when it is combined with Orphenadrine.
OuabainThe risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Ouabain.
OxaprozinThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Oxaprozin.
OxcarbazepineThe risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Oxcarbazepine.
OxprenololBendroflumethiazide may increase the hypotensive activities of Oxprenolol.
OxybutyninThe serum concentration of Bendroflumethiazide can be increased when it is combined with Oxybutynin.
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Bendroflumethiazide.
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Bendroflumethiazide.
OxyphenbutazoneThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Oxyphenbutazone.
OxyphenoniumThe serum concentration of Bendroflumethiazide can be increased when it is combined with Oxyphenonium.
PancuroniumThe serum concentration of Bendroflumethiazide can be increased when it is combined with Pancuronium.
PapaverineThe risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Papaverine.
ParamethasoneParamethasone may increase the hypokalemic activities of Bendroflumethiazide.
ParecoxibThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Parecoxib.
PargylineBendroflumethiazide may increase the hypotensive activities of Pargyline.
ParoxetineParoxetine may increase the hyponatremic activities of Bendroflumethiazide.
PasireotideBendroflumethiazide may increase the bradycardic activities of Pasireotide.
PenbutololBendroflumethiazide may increase the hypotensive activities of Penbutolol.
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Bendroflumethiazide.
PentobarbitalPentobarbital may increase the orthostatic hypotensive activities of Bendroflumethiazide.
PentoliniumBendroflumethiazide may increase the hypotensive activities of Pentolinium.
PentoxifyllinePentoxifylline may increase the hypotensive activities of Bendroflumethiazide.
PerindoprilBendroflumethiazide may increase the hypotensive activities of Perindopril.
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Bendroflumethiazide.
PhenelzinePhenelzine may increase the hypotensive activities of Bendroflumethiazide.
PhenforminThe therapeutic efficacy of Phenformin can be decreased when used in combination with Bendroflumethiazide.
PheniprazinePheniprazine may increase the hypotensive activities of Bendroflumethiazide.
PhenobarbitalPhenobarbital may increase the orthostatic hypotensive activities of Bendroflumethiazide.
PhenoxybenzamineBendroflumethiazide may increase the hypotensive activities of Phenoxybenzamine.
PhenoxypropazinePhenoxypropazine may increase the hypotensive activities of Bendroflumethiazide.
PhentolamineBendroflumethiazide may increase the hypotensive activities of Phentolamine.
PhenylbutazoneThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Phenylbutazone.
PhenylpropanolaminePhenylpropanolamine may increase the hypokalemic activities of Bendroflumethiazide.
PimecrolimusThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Pimecrolimus.
PinacidilBendroflumethiazide may increase the hypotensive activities of Pinacidil.
PindololBendroflumethiazide may increase the hypotensive activities of Pindolol.
PioglitazoneThe therapeutic efficacy of Pioglitazone can be decreased when used in combination with Bendroflumethiazide.
PipecuroniumThe serum concentration of Bendroflumethiazide can be increased when it is combined with Pipecuronium.
PirbuterolPirbuterol may increase the hypokalemic activities of Bendroflumethiazide.
PirenzepineThe serum concentration of Bendroflumethiazide can be increased when it is combined with Pirenzepine.
PirfenidoneThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Pirfenidone.
PirlindolePirlindole may increase the hypotensive activities of Bendroflumethiazide.
PiroxicamThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Piroxicam.
PivhydrazinePivhydrazine may increase the hypotensive activities of Bendroflumethiazide.
PolythiazideBendroflumethiazide may increase the hypotensive activities of Polythiazide.
Poractant alfaBendroflumethiazide may increase the bradycardic activities of Poractant alfa.
PramlintideThe therapeutic efficacy of Pramlintide can be decreased when used in combination with Bendroflumethiazide.
PrazosinBendroflumethiazide may increase the hypotensive activities of Prazosin.
PrednicarbatePrednicarbate may increase the hypokalemic activities of Bendroflumethiazide.
PrednisolonePrednisolone may increase the hypokalemic activities of Bendroflumethiazide.
PrednisonePrednisone may increase the hypokalemic activities of Bendroflumethiazide.
PregnenolonePregnenolone may increase the hypokalemic activities of Bendroflumethiazide.
PrimidonePrimidone may increase the orthostatic hypotensive activities of Bendroflumethiazide.
ProcaterolProcaterol may increase the hypokalemic activities of Bendroflumethiazide.
ProcyclidineThe serum concentration of Bendroflumethiazide can be increased when it is combined with Procyclidine.
PropacetamolThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Propacetamol.
PropafenoneBendroflumethiazide may increase the bradycardic activities of Propafenone.
PropanthelineThe serum concentration of Bendroflumethiazide can be increased when it is combined with Propantheline.
PropranololBendroflumethiazide may increase the hypotensive activities of Propranolol.
PTC299The therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with PTC299.
QuetiapineThe risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Quetiapine.
QuinaprilBendroflumethiazide may increase the hypotensive activities of Quinapril.
QuinidineThe serum concentration of Bendroflumethiazide can be increased when it is combined with Quinidine.
QuinineQuinine may increase the hypotensive activities of Bendroflumethiazide.
RamiprilRamipril may increase the hypotensive activities of Bendroflumethiazide.
RasagilineRasagiline may increase the hypotensive activities of Bendroflumethiazide.
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Bendroflumethiazide.
RemikirenRemikiren may increase the hypotensive activities of Bendroflumethiazide.
RepaglinideThe therapeutic efficacy of Repaglinide can be decreased when used in combination with Bendroflumethiazide.
RescinnamineBendroflumethiazide may increase the hypotensive activities of Rescinnamine.
ReserpineReserpine may increase the hypotensive activities of Bendroflumethiazide.
ResveratrolThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Resveratrol.
RimexoloneRimexolone may increase the hypokalemic activities of Bendroflumethiazide.
RiociguatBendroflumethiazide may increase the hypotensive activities of Riociguat.
RisperidoneBendroflumethiazide may increase the hypotensive activities of Risperidone.
RitodrineRitodrine may increase the hypokalemic activities of Bendroflumethiazide.
RituximabBendroflumethiazide may increase the hypotensive activities of Rituximab.
RivastigmineBendroflumethiazide may increase the bradycardic activities of Rivastigmine.
RofecoxibThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Rofecoxib.
RosiglitazoneThe therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Bendroflumethiazide.
RuxolitinibRuxolitinib may increase the bradycardic activities of Bendroflumethiazide.
SafrazineSafrazine may increase the hypotensive activities of Bendroflumethiazide.
SalbutamolSalbutamol may increase the hypokalemic activities of Bendroflumethiazide.
SalicylamideThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Salicylamide.
Salicylic acidThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Salicylic acid.
SalmeterolSalmeterol may increase the hypokalemic activities of Bendroflumethiazide.
SalsalateThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Salsalate.
SaprisartanBendroflumethiazide may increase the hypotensive activities of Saprisartan.
SaxagliptinThe therapeutic efficacy of Saxagliptin can be decreased when used in combination with Bendroflumethiazide.
ScopolamineThe serum concentration of Bendroflumethiazide can be increased when it is combined with Scopolamine.
Scopolamine butylbromideThe serum concentration of Bendroflumethiazide can be increased when it is combined with Scopolamine butylbromide.
SecobarbitalSecobarbital may increase the orthostatic hypotensive activities of Bendroflumethiazide.
SelegilineSelegiline may increase the hypotensive activities of Bendroflumethiazide.
SelexipagBendroflumethiazide may increase the hypotensive activities of Selexipag.
SeratrodastThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Seratrodast.
SertralineSertraline may increase the hyponatremic activities of Bendroflumethiazide.
SildenafilSildenafil may increase the antihypertensive activities of Bendroflumethiazide.
SitagliptinThe therapeutic efficacy of Sitagliptin can be decreased when used in combination with Bendroflumethiazide.
SitaxentanBendroflumethiazide may increase the hypotensive activities of Sitaxentan.
SolifenacinThe serum concentration of Bendroflumethiazide can be increased when it is combined with Solifenacin.
SotalolThe risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Sotalol.
SpiraprilBendroflumethiazide may increase the hypotensive activities of Spirapril.
SpironolactoneThe risk or severity of adverse effects can be increased when Spironolactone is combined with Bendroflumethiazide.
SRT501The therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with SRT501.
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Bendroflumethiazide.
SufentanilBendroflumethiazide may increase the bradycardic activities of Sufentanil.
SulfasalazineThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Sulfasalazine.
SulindacThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Sulindac.
SulodexideThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Bendroflumethiazide.
SulpirideThe risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Sulpiride.
SuprofenThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Suprofen.
TadalafilTadalafil may increase the antihypertensive activities of Bendroflumethiazide.
TapentadolThe risk or severity of adverse effects can be increased when Tapentadol is combined with Bendroflumethiazide.
TelmisartanBendroflumethiazide may increase the hypotensive activities of Telmisartan.
TemocaprilBendroflumethiazide may increase the hypotensive activities of Temocapril.
TenoxicamThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Tenoxicam.
TepoxalinThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Tepoxalin.
TerazosinThe risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Terazosin.
TerbutalineTerbutaline may increase the hypokalemic activities of Bendroflumethiazide.
TeriflunomideThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Teriflunomide.
TerlipressinBendroflumethiazide may increase the hypotensive activities of Terlipressin.
ThiamylalThiamylal may increase the orthostatic hypotensive activities of Bendroflumethiazide.
ThiopentalThiopental may increase the orthostatic hypotensive activities of Bendroflumethiazide.
Tiaprofenic acidThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Tiaprofenic acid.
TiboloneBendroflumethiazide may increase the hypotensive activities of Tibolone.
TicrynafenBendroflumethiazide may increase the hypotensive activities of Ticrynafen.
TimololTimolol may increase the hypotensive activities of Bendroflumethiazide.
TiotropiumThe serum concentration of Bendroflumethiazide can be increased when it is combined with Tiotropium.
TixocortolTixocortol may increase the hypokalemic activities of Bendroflumethiazide.
TizanidineThe risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Tizanidine.
TofacitinibTofacitinib may increase the bradycardic activities of Bendroflumethiazide.
TolazamideThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Bendroflumethiazide.
TolazolineBendroflumethiazide may increase the hypotensive activities of Tolazoline.
TolbutamideThe therapeutic efficacy of Tolbutamide can be decreased when used in combination with Bendroflumethiazide.
Tolfenamic AcidThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Tolfenamic Acid.
TolmetinThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Tolmetin.
ToloxatoneToloxatone may increase the hypotensive activities of Bendroflumethiazide.
TolterodineThe serum concentration of Bendroflumethiazide can be increased when it is combined with Tolterodine.
TopiramateBendroflumethiazide may increase the hypokalemic activities of Topiramate.
TorasemideTorasemide may increase the hypotensive activities of Bendroflumethiazide.
ToremifeneBendroflumethiazide may increase the hypercalcemic activities of Toremifene.
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Bendroflumethiazide.
TrandolaprilBendroflumethiazide may increase the hypotensive activities of Trandolapril.
TranilastThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Tranilast.
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Bendroflumethiazide.
TranylcypromineTranylcypromine may increase the hypotensive activities of Bendroflumethiazide.
TravoprostTravoprost may increase the hypotensive activities of Bendroflumethiazide.
TrazodoneTrazodone may increase the hyponatremic activities of Bendroflumethiazide.
TreprostinilTreprostinil may increase the hypotensive activities of Bendroflumethiazide.
TriamcinoloneTriamcinolone may increase the hypokalemic activities of Bendroflumethiazide.
TriamtereneThe risk or severity of adverse effects can be increased when Triamterene is combined with Bendroflumethiazide.
TrichlormethiazideBendroflumethiazide may increase the hypotensive activities of Trichlormethiazide.
TrihexyphenidylThe serum concentration of Bendroflumethiazide can be increased when it is combined with Trihexyphenidyl.
TrimazosinBendroflumethiazide may increase the hypotensive activities of Trimazosin.
TrimethaphanBendroflumethiazide may increase the hypotensive activities of Trimethaphan.
Trisalicylate-cholineThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Trisalicylate-choline.
TroglitazoneThe therapeutic efficacy of Troglitazone can be decreased when used in combination with Bendroflumethiazide.
TropicamideThe serum concentration of Bendroflumethiazide can be increased when it is combined with Tropicamide.
TrospiumThe serum concentration of Bendroflumethiazide can be increased when it is combined with Trospium.
TubocurarineThe serum concentration of Bendroflumethiazide can be increased when it is combined with Tubocurarine.
UdenafilUdenafil may increase the antihypertensive activities of Bendroflumethiazide.
UmeclidiniumThe serum concentration of Bendroflumethiazide can be increased when it is combined with Umeclidinium.
UnoprostoneBendroflumethiazide may increase the hypotensive activities of Unoprostone.
ValdecoxibThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Valdecoxib.
ValsartanValsartan may increase the hypotensive activities of Bendroflumethiazide.
VardenafilVardenafil may increase the antihypertensive activities of Bendroflumethiazide.
VecuroniumThe serum concentration of Bendroflumethiazide can be increased when it is combined with Vecuronium.
VerapamilThe risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Verapamil.
VilanterolVilanterol may increase the hypokalemic activities of Bendroflumethiazide.
VilazodoneVilazodone may increase the hyponatremic activities of Bendroflumethiazide.
VildagliptinThe therapeutic efficacy of Vildagliptin can be decreased when used in combination with Bendroflumethiazide.
VogliboseThe therapeutic efficacy of Voglibose can be decreased when used in combination with Bendroflumethiazide.
VortioxetineVortioxetine may increase the hyponatremic activities of Bendroflumethiazide.
XylometazolineBendroflumethiazide may increase the hypotensive activities of Xylometazoline.
YohimbineYohimbine may decrease the antihypertensive activities of Bendroflumethiazide.
ZaltoprofenThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Zaltoprofen.
ZileutonThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Zileuton.
ZimelidineZimelidine may increase the hyponatremic activities of Bendroflumethiazide.
ZomepiracThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Zomepirac.
Food Interactions
  • Take with food to increase bioavailability.

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Transporter activity
Specific Function:
Key mediator of sodium and chloride reabsorption in this nephron segment, accounting for a significant fraction of renal sodium reabsorption.
Gene Name:
SLC12A3
Uniprot ID:
P55017
Molecular Weight:
113138.04 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  2. Monroy A, Plata C, Hebert SC, Gamba G: Characterization of the thiazide-sensitive Na(+)-Cl(-) cotransporter: a new model for ions and diuretics interaction. Am J Physiol Renal Physiol. 2000 Jul;279(1):F161-9. [PubMed:10894798 ]
  3. Vallon V, Rieg T, Ahn SY, Wu W, Eraly SA, Nigam SK: Overlapping in vitro and in vivo specificities of the organic anion transporters OAT1 and OAT3 for loop and thiazide diuretics. Am J Physiol Renal Physiol. 2008 Apr;294(4):F867-73. doi: 10.1152/ajprenal.00528.2007. Epub 2008 Jan 23. [PubMed:18216144 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inducer
General Function:
Voltage-gated potassium channel activity
Specific Function:
Potassium channel activated by both membrane depolarization or increase in cytosolic Ca(2+) that mediates export of K(+). It is also activated by the concentration of cytosolic Mg(2+). Its activation dampens the excitatory events that elevate the cytosolic Ca(2+) concentration and/or depolarize the cell membrane. It therefore contributes to repolarization of the membrane potential. Plays a key ...
Gene Name:
KCNMA1
Uniprot ID:
Q12791
Molecular Weight:
137558.115 Da
References
  1. Tricarico D, Barbieri M, Mele A, Carbonara G, Camerino DC: Carbonic anhydrase inhibitors are specific openers of skeletal muscle BK channel of K+-deficient rats. FASEB J. 2004 Apr;18(6):760-1. Epub 2004 Feb 6. [PubMed:14766795 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Zinc ion binding
Specific Function:
Reversible hydration of carbon dioxide. Can hydrates cyanamide to urea.
Gene Name:
CA1
Uniprot ID:
P00915
Molecular Weight:
28870.0 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Zinc ion binding
Specific Function:
Essential for bone resorption and osteoclast differentiation (By similarity). Reversible hydration of carbon dioxide. Can hydrate cyanamide to urea. Involved in the regulation of fluid secretion into the anterior chamber of the eye. Contributes to intracellular pH regulation in the duodenal upper villous epithelium during proton-coupled peptide absorption. Stimulates the chloride-bicarbonate ex...
Gene Name:
CA2
Uniprot ID:
P00918
Molecular Weight:
29245.895 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Zinc ion binding
Specific Function:
Reversible hydration of carbon dioxide. May stimulate the sodium/bicarbonate transporter activity of SLC4A4 that acts in pH homeostasis. It is essential for acid overload removal from the retina and retina epithelium, and acid release in the choriocapillaris in the choroid.
Gene Name:
CA4
Uniprot ID:
P22748
Molecular Weight:
35032.075 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Thiopurine s-methyltransferase activity
Specific Function:
Catalyzes the S-methylation of thiopurine drugs such as 6-mercaptopurine.
Gene Name:
TPMT
Uniprot ID:
P51580
Molecular Weight:
28180.09 Da
References
  1. Lysaa RA, Giverhaug T, Wold HL, Aarbakke J: Inhibition of human thiopurine methyltransferase by furosemide, bendroflumethiazide and trichlormethiazide. Eur J Clin Pharmacol. 1996;49(5):393-6. [PubMed:8866635 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23